Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 4/20 | 0.67 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.67 |
| ▸ | PDE2A | O00408 | 2/20 | 0.67 |
| ▸ | PDE5A | O76074 | 2/20 | 0.60 |
| ▸ | CCNK | O75909 | 2/20 | 0.43 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.43 |
| ▸ | CDK1 | P06493 | 4/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6316815 | 0.82 | PDE3B (0.61) | PDE3BPDE3APDE2APDE5ACCNK | |
| SCHEMBL4001024 | 0.80 | PDE3B (0.58) | PDE3BPDE3APDE2APDE5AAPP | |
| SCHEMBL6319303 | 0.80 | PDE3B (1.00) | PDE3BPDE3APDE2APDE5A | |
| SCHEMBL6317888 | 0.77 | PDE3B (0.78) | PDE3BPDE3APDE2APDE5ACCNK | |
| SCHEMBL6317737 | 0.77 | PDE3B (0.45) | PDE3BPDE3APDE2APDE5A | |
| SCHEMBL6323438 | 0.76 | PDE3B (0.90) | PDE3BPDE3APDE2APDE5A | |
| SCHEMBL6318018 | 0.76 | PDE3B (0.87) | PDE3BPDE3APDE2APDE5A | |
| SCHEMBL6317556 | 0.74 | PDE3B (0.61) | PDE3BPDE3APDE2ACDK1 | |
| SCHEMBL5528087 | 0.74 | PDE3B (0.75) | PDE3BPDE3APDE2APDE5AAPP | |
| SCHEMBL300168 | 0.72 | PDE5A (0.71) | PDE3BPDE3APDE2APDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6838559-B2 | Purine inhibitors of phosphodiesterase (PDE) 7 | BRISTOL-MYERS SQUIBB CO. (US) | 2005-01-04 | — | — | US | claimed |
| EP-1499286-A1 | STABILIZED BODY CARE PRODUCTS, HOUSEHOLD PRODUCTS, TEXTILES AND FABRICS | Ciba SC Holding AG (CH) | 2005-01-26 | — | — | EP | disclosed |
| US-6838559-B2 | Purine inhibitors of phosphodiesterase (PDE) 7 | BRISTOL-MYERS SQUIBB CO. (US) | 2005-01-04 | — | — | US | disclosed |
| WO-2003103622-A1 | STABILIZED BODY CARE PRODUCTS, HOUSEHOLD PRODUCTS, TEXTILES AND FABRICS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-12-18 | — | — | WO | disclosed |
| US-20030104974-A1 | Dual inhibitorsof PDE 7 and PDE 4 | BRISTOL-MYERS SQUIBB COMPANY | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030104974-A1 | Dual inhibitorsof PDE 7 and PDE 4 | PDE4A, PDE4B, PDE7B | PDE3B 10/4885PDE3A 13/4885PDE2A 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.